Clinical Trials
26 trialsNCT07566156 2026-05-11
EV-309
Astellas Pharma Inc
Phase 3 Recruiting
NCT05643963 2025-12-11
The COOKER-BLADDER Trial
Hospital Centre Biel/Bienne
Phase NA Completed
NCT05726786 2025-12-09
INCyst
Centre Hospitalier Universitaire Vaudois
Phase 3 Recruiting
NCT05241340 2025-10-24
RAD-VACCINE
The Methodist Hospital Research Institute
Phase 2 Active not recruiting
NCT06237920 2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT04442724 2025-08-14
FMBRT
Cedars-Sinai Medical Center
Phase NA Recruiting
NCT03081858 2025-06-27
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Phase 1/2 Completed
NCT06337942 2025-02-12
Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study
University of California, Los Angeles
Phase NA Recruiting
NCT04167631 2024-10-30
Can VI-RADS/ADC Accurately Stage Bladder Cancer??
Mansoura University
Phase NA Active not recruiting
NCT04200963 2024-03-15
A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma
Ikena Oncology
Phase 1 Completed
NCT02901548 2022-07-29
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT04922047 2021-06-11
TACBIN-01
RenJi Hospital
Phase 1/2 Unknown
NCT03257293 2021-04-27
A Trial of a Modified Cystoscopy Method to Reduce Pain Perception
Western University, Canada
Phase NA Completed
NCT03123055 2020-03-18
FIERCE-22
Rainier Therapeutics
Phase 1/2 Terminated
NCT02401542 2020-03-09
FIERCE-21
Rainier Therapeutics
Phase 1/2 Terminated
NCT03591367 2019-11-04
The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation
Mansoura University
Phase NA Completed
NCT02300610 2019-08-01
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01310803 2017-10-05
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
Endo Pharmaceuticals
Phase 3 Terminated
NCT01200992 2017-08-24
EMBARC-RF
Bioniche Life Sciences Inc.
Phase 3 Terminated
NCT01803295 2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA Completed
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT02891460 2016-09-08
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
UroGen Pharma Ltd.
Phase NA Completed
NCT01799499 2015-09-01
NMIBC TURBT HG
UroGen Pharma Ltd.
Phase NA Withdrawn
NCT02254915 2015-04-01
SHTC-EUROPE-1
Medical Enterprises Europe B.V.
Phase 3 Withdrawn
NCT00753415 2015-03-17
A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00384891 2014-10-07
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
Medical Enterprises Europe B.V.
Phase 3 Terminated